59 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
candidates are designed to treat, expectations for the markets for certain therapeutics, our ability to execute our clinical and regulatory goals
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
, expectations for the markets for certain therapeutics, our ability to execute our clinical and regulatory goals and deploy regulatory guidance towards
8-K
EX-99.1
bso0k5c t2umo3zhm5w
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
424B5
2cmrabdbjptpfzxxd9
15 Jun 23
Prospectus supplement for primary offering
4:54pm
8-K
EX-99.1
oohqn 9tsn072qqdje8b
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am
8-K
EX-99.1
jt9kp 74yeceusk3
10 Apr 23
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
8:30am
8-K
EX-99.1
ojaosvhem3e
15 Aug 22
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
8:00am
8-K
EX-99.1
b3c hsxxw
11 May 22
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
8:30am
8-K
EX-99.1
qw4 f9i31npelr2
23 Mar 22
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
4:05pm
8-K
EX-99.1
7w5830qp8j7kaj5
22 Dec 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
q40r7sw10zyjlnx8l
15 Nov 21
Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development
8:00am
424B5
5v6te
5 May 21
Prospectus supplement for primary offering
4:01pm